The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of nivolumab for locally advanced or metastatic cutaneous cell carcinoma (NIVOSQUACS trial).
 
Roland Lang
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Peter Koelblinger
Stock and Other Ownership Interests - Bayer; BioNTech; Moderna Therapeutics; Valneva
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi Aventis GmbH
Speakers' Bureau - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi Aventis GmbH
 
Erika Richtig
Honoraria - Amgen; Bayer; Bristol-Myers Squibb; Merck; Merck Sharp Dohme; Novartis; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Merck; Merck Sharp & Dohme; Novartis; Pierre Fabre
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Merck; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); CureVac (Inst); Incyte (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pierre Fabre (Inst); Regeneron (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; Sanofi
 
Ingrid Wolf
Honoraria - Merck; Merck Sharp & Dohme; Pierre Fabre; Sanofi Aventis GmbH
Consulting or Advisory Role - Merck; Merck Sharp & Dohme; Pierre Fabre; Sanofi Aventis GmbH
 
Christoph Hoeller
Honoraria - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche; Sanofi Aventis GmbH
Research Funding - Amgen (Inst)
 
Christine Hafner
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre
 
Van Anh Nguyen
Honoraria - Bristol-Myers Squibb; Kyowa Kirin; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi Aventis GmbH
Consulting or Advisory Role - Bristol-Myers Squibb; Kyowa Kirin; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi Aventis GmbH
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pierre Fabre; Sanofi Aventis GmbH
 
Julian Kofler
Stock and Other Ownership Interests - Gilead Sciences; Moderna Therapeutics
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi Aventis GmbH
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi Aventis GmbH
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi Aventis GmbH
 
Matthias Barta
Consulting or Advisory Role - Merck Sharp & Dohme; Pierre Fabre
Travel, Accommodations, Expenses - Abbvie
 
Wolfgang Hitzl
No Relationships to Disclose
 
Martin Laimer
Honoraria - Amryt Pharma
Research Funding - Bristol-Myers Squibb; Onconova Therapeutics